This is a research study to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women (LTW), to standard of care mental health and substance use screening. Pregnant and postpartum women ages 18-41 who are receiving prenatal care within the MUSC Health system or who delivered within the MUSC Health System are invited to participate.
The main purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in adults with severe postpartum depression (PPD). SAGE-217 is is an investigational drug, which means that it is not yet approved to treat PPD. Participation in the study will last up to 76 days and includes a 14 day treatment period where SAGE-217 is taken by oral pill daily. Visits will take approximately 1 to 3 hours.
The primary purpose of this study is to compare extended-release buprenorphine (CAM2038) to buprenorphine placed under the tongue (sublingual) in pregnant women with opioid use disorder to see if CAM2038 is as effective as sublingual buprenorphine. We are looking to recruit pregnant women who are between 18-41 years old; are between 6-30 weeks pregnant and are not planning to terminate the pregnancy; have opioid use disorder, and are enrolled or are planning to enroll in outpatient buprenorphine treatment at The Medical University of South Carolina. Participation in the study would last between 13 and 21 months total with up to between about 63-102 total visits, including weekly medication check visits and research visits.
Staff at sites who participate in the MUSC Women's Reproductive Behavioral Telehealth (WRBT) Program will be asked to participate in individual interviews or focus groups (group discussions) about their experience with the telemedicine program and fill out surveys. Patients in the WRBT Program will be asked to fill out surveys about their telemedicine experience.
This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder, as well as a text message based mental health and substance use screening and treatment program for pregnant and postpartum women, called Listening to Women (LTW). Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years of any race who misuse opioids or have opioid use disorder, obstetric providers who treat pregnant women with opioid misuse and opioid use disorder and women who self-identify as Black that has been pregnant or postpartum in the past 2 years and struggled with a substance use disorder or mental health disorder during this time OR did NOT struggle with a substance use disorder or mental health disorder during this time to participate in this study.
This is an open-label study designed to investigate the feasibility and tolerability of a novel TMS treatment protocol to treat depression in women with post-partum depression. It is known that TMS can effectively treat depression. The FDA approved protocol lasts 6 weeks and is not feasible for many women with post-partum depression. We are investigating a 3 day treatment for depression which may be more acceptable for this population. We further hope to characterize the ant-depressant effect of this protocol in order to design a larger trial.